Filing Flows

Filing Flows › Health Care › Phibro Animal Health (PAHC)

Phibro Animal Health (PAHC) earnings and revenue breakdown

Latest: Q1 FY27 · 10-Q filed Nov 4, 2026 · Phibro Animal Health (PAHC) Q1 FY27 earnings results →

Q1 FY27 Revenue up 6% year over year to $387M · 8¢ of every $1 of revenue kept as net profit · operating margin 12.8%

Phibro Animal Health made $387M in Q1 FY27 (+6% Y/Y): Animal Health $293M, Mineral Nutrition $73.6M, Performance Products $20.2M. Operating margin 12.8%, net earnings $29.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.

Revenue$387M
Year over year+6%
Operating margin12.8%
Net earnings$29.5M
Operating cash flow$26.1M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $386.8M in Q1 FY27, up 6% year over year and down 3% from the previous quarter. MFAs and other was the largest line at 53% of revenue. MFAs and other added $11.3M year over year (up 6%), 49% of the total change. Nutritional Specialties declined 2%.

Gross margin was 33.2%, up 0.3 points from Q1 FY26. Operating profit was $49.6M, a 12.8% margin (down 1.3 points year over year). Operating profit fell $1.6M even though revenue rose $22.9M versus Q1 FY26, so costs grew faster than sales. Operating expenses grew 15% against revenue growth of 6%. Net earnings were $29.5M, up 11% year over year. The effective tax rate was 23.9%.

Operating cash flow was $26.1M (up 180% year over year), 88% of net earnings. Non-cash charges added back $13.6M of depreciation and amortization and $804K of share-based compensation. Working capital and other items used $17.8M. Capital expenditures of $18.8M left free cash flow of $7.3M.

Quarterly history

Phibro Animal Health revenue by quarterPhibro Animal Health revenue by quarter$348MQ3 FY25$379MQ4 FY25$364MQ1 FY26$374MQ2 FY26$384MQ3 FY26$397MQ4 FY26$387MQ1 FY27
Phibro Animal Health net earnings by quarterPhibro Animal Health net earnings by quarter$20.9MQ3 FY25$17.2MQ4 FY25$26.5MQ1 FY26$27.5MQ2 FY26$24.0MQ3 FY26$21.7MQ4 FY26$29.5MQ1 FY27
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q1 FY2710-QNov 4, 2026$387M+6%12.8%$29.5M$26.1M
Q4 FY2610-KAug 26, 2026$397M+5%12.1%$21.7M$24.1M
Q3 FY2610-QMay 6, 2026$384M+10%11.6%$24.0M$16.2M
Q2 FY2610-QFeb 4, 2026$374M+21%13.5%$27.5M$19.4M
Q1 FY2610-QNov 5, 2025$364M+40%14.1%$26.5M$9.3M
Q4 FY2510-KAug 27, 2025$379M+39%8.9%$17.2M$21.3M
Q3 FY2510-QMay 7, 2025$348M+32%9.6%$20.9M$43.2M

Charts

Phibro Animal Health: revenue growth, year over year and quarter over quarterPhibro Animal Health: revenue growth, year over year and quarter over quarterY/YQ/Q+32%Q3 FY25+39%+9%Q4 FY25+40%-4%Q1 FY26+21%+3%Q2 FY26+10%+3%Q3 FY26+5%+3%Q4 FY26+6%-3%Q1 FY27
Latest (Q1 FY27): Y/Y +6%, Q/Q -3%.
Phibro Animal Health: where the cash came from (+) and went (−), TTM to Q1 FY27Phibro Animal Health: where the cash came from (+) and went (−), TTM to Q1 FY27Operating cash flow$85.7MCapital spending−$64.1MDividends−$19.5MOther financing−$18.1MNet borrowing (+) / repaid (−)$9.0MOther investing$7.7MCash drawn (+) / kept (−)−$2.8MExchange rates$2.0M
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Phibro Animal Health: profit against cash, quarter by quarterPhibro Animal Health: profit against cash, quarter by quarterNet incomeOperating cash flow$3.2M$3.1MQ2 FY25$20.9M$43.2MQ3 FY25$17.2M$21.3MQ4 FY25$26.5M$9.3MQ1 FY26$27.5M$19.4MQ2 FY26$24.0M$16.2MQ3 FY26$21.7M$24.1MQ4 FY26$29.5M$26.1MQ1 FY27
Latest (Q1 FY27): Net income $29.5M, Operating cash flow $26.1M.
Phibro Animal Health: diluted shares by fiscal yearPhibro Animal Health: diluted shares by fiscal year41MFY2141MFY2241MFY2341MFY2441MFY2541MFY26
+1.1% since FY21: more shares outstanding (issuance, stock pay).
Phibro Animal Health in its industry: growth against margin (225 companies, SIC 2834)Phibro Animal Health in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMPAHC (+6%, 13%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Phibro Animal Health

Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise and care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. We market approximately 790 product lines in approximately 90 countries to approximately 4,800 customers. We develop, manufacture and market a broad range of products for food animals including poultry, beef and dairy cattle, swine, aquaculture and dogs. Our products help prevent, control and treat diseases and support nutrition to help improve animal health and well-being.

In its own words, from its 10-K, filed Aug 26, 2026.

Phibro Animal Health against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +6% against the peers' median +7%. Operating margin: 12.8% against the peers' median 20.4%.

CompanyQuarterRevenueY/YOp. margin
PAHC Phibro Animal HealthQ1 FY27$387M+6%12.8%
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Phibro Animal Health 10-Q on SEC EDGAR · CIK 1069899 · Pharmaceutical Preparations

Guidance and outlook

Phibro Animal Health Revenue: guidance against what was reportedPhibro Animal Health Revenue: guidance against what was reportedguided rangereported (above / within / below)FY26$1.5BFY27
Met or beat 1 of 1 guided periods. Grey: the last range guided before the figures came out; dot: the reported figure.
Phibro Animal Health: what its forward-looking statements are about (10-Q filed 2026-11-04)Phibro Animal Health: what its forward-looking statements are about (10-Q filed 2026-11-04)Other8Costs4Financing3Tax1Supply chain1Buybacks & dividends1
18 statements; tone +0.22 (−1 all cautious, +1 all confident); 7 hedged.
Phibro Animal Health: outlook statements against the filing beforePhibro Animal Health: outlook statements against the filing beforeConfident4

13F: who owns PAHC and who is buying

Largest holders of PAHC (13F)Largest holders of PAHC (13F)BlackRock$101MFMR LLC$99.2MVanguard Group$57.5MState Street$32.6MMillennium Management LLC$29.4MVanguard Capital Management LLC$29.0MGeode Capital Management, LLC$20.6MLord, Abbett & Co. LLC$20.5MDimensional Fund Advisors LP$16.7MVanguard Portfolio Management LLC$16.0M
Funds' net buying of PAHC by quarter (13F)Funds' net buying of PAHC by quarter (13F)−$13.1M2024-09−$22.7M2024-12−$8.5M2025-03$451K2025-06−$42.2M2025-09−$3.8M2025-12$53.1M2026-03$27.7M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on PAHC

History

Every quarter: Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results

Compare PAHC with

中文版：Phibro Animal Health（PAHC）财报

Español · Français